



PARKINSON'S DISEASE NEWS

<http://www.viartis.net/parkinsons.disease/news.htm>

28th December 2014 - New research

EFFECT OF PRAMIPEXOLE ER FOR PARKINSON'S DISEASE

The long term use of pramipexole as a once-daily extended-release oral formulation in early or advanced Parkinson's Disease demonstrated efficacy, but also adverse events. Pramipexole is a dopamine agonist that is most widely sold as Mirapex ER. For more information go to : <http://www.rxlist.com/mirapex-er-drug.htm>



In early Parkinson's Disease the main adverse events of extended release pramipexole were somnolence (15%), peripheral edema (11%) and back pain (10%). In advanced Parkinson's Disease the main adverse events were dyskinesia (27%) and somnolence (13%).

Parkinson's Disease symptom scores (using the UPDRS) were improved in early Parkinson's Disease, with reductions of 6.6 and 6.3 points. In advanced Parkinson's Disease the scores were reduced even further, by 11.5 and 9.1 points after over two years.

These results support the long-term efficacy of pramipexole ER in early and advanced Parkinson's Disease. Adverse Events were typical for dopaminergic medications. UPDRS (Parkinson's Disease) scores suggested sustained symptomatic benefit.

Reference : European Journal of Neurology [2014] 21 (5) : 736-743 (R.A.Hauser, A.H. Schapira, P.Barone, Y.Mizuno, O.Rascol, M.Busse, C.Debieuvre, M.Fraessdorf, W.Poewe)
Complete abstract : <http://www.ncbi.nlm.nih.gov/pubmed/24834511>

<http://www.viartis.net/parkinsons.disease/news/141228.pdf>

mail@viartis.net

©2014 Viartis